Novo Sues Orbicular to Block Copies of Saxenda Weight-Loss Drug

Novo Nordisk AS alleges that a generic version of Saxenda proposed by Orbicular Pharmaceutical Technologies Pvt. Ltd. infringes 18 patents for the injectable weight-loss treatment, according to a federal lawsuit in Delaware.

Novo’s complaint, filed June 24 in the US District Court for the District of Delaware, expands its legal fight over patents related to Saxenda, many of which it’s also asserting in pending cases over its blockbuster diabetes drug Ozempic.

The drug’s main patent, which covers Saxenda’s active ingredient and methods of making and using it, isn’t part of the Orbicular suit. It expires in February 2023, ...